Loading…
MiMedx Group, Inc. is projected to rise to $4.30 by 2027, a +5% move from its current price of $4.11. MDXG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $4.04 | $4.11 | $4.19 | +0.01% |
| Jul 15 | $4.00 | $4.11 | $4.22 | +0.01% |
| Jul 16 | $3.98 | $4.11 | $4.24 | +0.02% |
| Jul 17 | $3.96 | $4.11 | $4.27 | +0.02% |
| Jul 18 | $3.94 | $4.11 | $4.28 | +0.03% |
| Jul 19 | $3.93 | $4.11 | $4.30 | +0.03% |
| Jul 20 | $3.92 | $4.11 | $4.32 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.92 | $4.11 | $4.32 | +0.04% |
| Week 2 | $3.84 | $4.11 | $4.41 | +0.08% |
| Week 3 | $3.78 | $4.11 | $4.48 | +0.12% |
| Week 4 | $3.73 | $4.12 | $4.54 | +0.16% |
| Week 5 | $3.69 | $4.12 | $4.59 | +0.20% |
| Week 6 | $3.66 | $4.12 | $4.64 | +0.24% |
| Week 7 | $3.62 | $4.12 | $4.69 | +0.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.
Its processing employs aseptic processing techniques in addition to terminal sterilization.
The wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare.
It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings.
The company was founded in 2006 and is headquartered in Marietta, Georgia.
MiMedx Group, Inc. (MDXG) is a healthcare company trading in the sector. The current price is $4.26 per share, with a market capitalization of $634.51M and a rank of 2868 by market cap.
A major floor 24.8% below — a decisive break under it would weaken the trend.
The nearest floor, 13.1% below — buyers have tended to step in here.
The nearest ceiling, 3.6% above — a clean break opens room to run.
A major ceiling 17.3% above — clearing it would confirm fresh momentum.
Key MDXG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MDXG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.16 | Sell | $4.12 | Sell |
| MA 10 | $4.03 | Buy | $4.04 | Buy |
| MA 20 | $3.87 | Buy | $3.93 | Buy |
| MA 50 | $3.71 | Buy | $3.86 | Buy |
| MA 100 | $3.97 | Buy | $4.17 | Sell |
| MA 200 | $5.26 | Sell | $4.91 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.92 | Neutral |
| Stoch RSI (14) | 52.95 | Neutral |
| CCI (20) | 96.99 | Neutral |
| Williams %R (14) | -25.42 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 10.19 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 74.58 | Neutral |
| TRIX (15) | 0.37 | Buy |
| Awesome (5,34) | 0.38 | Buy |
| Ultimate (7,14,28) | 71.65 | Sell |
| Momentum (10) | 0.30 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 4.25 | Sell |
| ADX (14) | 20.16 | Buy |
| ATR (14) | 0.07 | Info |
Near-term technical picture shows a NEUTRAL stance. The RSI(14) is 70, with the 50-day simple moving average at $3.68 and the 200-day simple moving average at $5.29. Support is listed at $3.57 and resistance at $4.26.
The 30-day trading range spans from $3.77 to $4.82, indicating limited near-term movement within a tight band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.09 | $4.11 | $5.12 | 0% | Neutral | |
| $3.52 | $4.30 | $5.49 | +5% | Neutral | |
| $3.69 | $4.58 | $6.01 | +12% | Neutral | |
| $3.87 | $4.89 | $6.54 | +19% | Neutral | |
| $4.08 | $5.22 | $7.12 | +27% | Bullish | |
| $4.96 | $6.43 | $8.90 | +56% | Bullish | |
| $5.34 | $7.00 | $9.83 | +70% | Bullish | |
| $5.19 | $6.87 | $9.77 | +67% | Bullish | |
| $5.59 | $7.48 | $10.77 | +82% | Bullish | |
| $5.64 | $7.62 | $11.08 | +85% | Bullish | |
| $8.41 | $11.84 | $18.06 | +188% | Bullish | |
| $12.71 | $19.20 | $31.39 | +367% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.09 | $4.11 | $4.95 | +0.00% |
| August 2026 | $3.61 | $4.22 | $5.04 | +2.67% |
| September 2026 | $3.51 | $4.13 | $4.98 | -2.10% |
| October 2026 | $3.51 | $4.14 | $5.02 | +0.23% |
| November 2026 | $3.56 | $4.22 | $5.14 | +1.86% |
| December 2026 | $3.51 | $4.18 | $5.12 | -0.94% |
Click any year to see its month-by-month MDXG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The MDXG price prediction for 2026 points to an average of $4.11 (low $3.09, high $5.12) — a potential gain of 0% on today's $4.11. A consolidation phase looks the most probable path here.
In 2027, MDXG is projected to trade between $3.52 and $5.49, averaging $4.30 — a potential gain of +5% from today's $4.11. That is up +5% on the projected 2026 average. Price action looks broadly range-bound.
MiMedx Group, Inc.'s 2028 outlook centres on $4.58, within a $3.69 to $6.01 range. That is up +7% on the projected 2027 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, MDXG could reach as high as $6.54, with a base case around $4.89 and support toward $3.87 — roughly +19% from $4.11. Price action looks broadly range-bound.
Expect MDXG to range from $4.08 to $7.12 through 2030. The $5.22 average target implies a +27% move from current prices. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The MDXG price prediction for 2031 points to an average of $6.43 (low $4.96, high $8.90) — a potential gain of +56% on today's $4.11. Momentum favours further upside here.
In 2032, MDXG is projected to trade between $5.34 and $9.83, averaging $7.00 — a potential gain of +70% from today's $4.11. That is up +9% on the projected 2031 average. Buyers look set to stay in control over this stretch.
MiMedx Group, Inc.'s 2033 outlook centres on $6.87, within a $5.19 to $9.77 range. That is -2% versus the projected 2032 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2034, MDXG could reach as high as $10.77, with a base case around $7.48 and support toward $5.59 — roughly +82% from $4.11. Buyers look set to stay in control over this stretch.
Expect MDXG to range from $5.64 to $11.08 through 2035. The $7.62 average target implies a +85% move from current prices. That is up +2% on the projected 2034 average. Momentum favours further upside here.
The MDXG price prediction for 2040 points to an average of $11.84 (low $8.41, high $18.06) — a potential gain of +188% on today's $4.11. Buyers look set to stay in control over this stretch.
In 2050, MDXG is projected to trade between $12.71 and $31.39, averaging $19.20 — a potential gain of +367% from today's $4.11. That is up +62% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in MDXG today (≈ 243.309002 MDXG) could be worth
$4,671.13
+$3,671.13 (+367%) by 2050 · US Dollar
Based on the average projected MDXG price of $19.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MDXGwould be worth at today's price.
$1,000 invested in MDXG on Jul 10, 2025 (≈ 147.492621 MDXG) would be worth
$606.19
-$393.81 (-39.4%) today · 0.61× · US Dollar
Based on a MDXG entry price of $6.78 vs. today's $4.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.95 | $1,040.51 | +4.1% |
| 1 month ago | $3.64 | $1,129.12 | +12.9% |
| 3 months ago | $3.87 | $1,062.02 | +6.2% |
| 6 months ago | $6 | $685 | -31.5% |
| 1 year ago | $6.78 | $606.19 | -39.4% |
| All time (5.0y) ago | $11.5 | $357.39 | -64.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MDXG forecast.
Our base-case forecast reaches $8.20 around 2040.
Implied market cap at $8.20: $1.22B
The multi-year forecast depicts a gradually rising trajectory. For 2026 the min is $3.09, avg $4.26, max $5.31 with ROI 0 and NEUTRAL sentiment. By 2027 the avg is $4.50, max $5.74, min $3.68 with ROI 5.6 and NEUTRAL sentiment, and by 2028 the avg rises to $4.80, max $6.29, min $3.85 with ROI 12.6.
In 2029 the avg is $5.11, max $6.84, min $4.04 with ROI 19.9 and NEUTRAL sentiment. In 2030 the avg is $5.53, max $7.54, min $4.32 with ROI 29.8 and sentiment BULLISH. The forecast continues to reflect a bullish tilt beyond 2030, with 2031 avg $6.80, 2032 avg $7.37, 2033 avg $7.27, 2034 avg $7.93, and 2035 avg $8.06, all with rising ROIs and BULLISH sentiment in the later years.
By 2040, the avg price is forecast at $12.63 with a max of $19.26 and min of $8.97, delivering a substantial ROI of 196.4 and a BULLISH sentiment. By 2050 the avg is projected to $20.52, with a max of $33.56 and min of $13.59, corresponding to an ROI of 381.8% and a BULLISH sentiment. These figures point to a long-run upside, tempered by the inherent uncertainty of markets and execution risk.
Tap a question to reveal the answer.
Average price: $5.53; minimum: $4.32; maximum: $7.54; ROI: 29.8%; sentiment: BULLISH.
The long-range forecast shows a bullish trajectory from 2030 onward, with the average price rising to $5.53 by 2030 and to $20.52 by 2050, and ROIs climbing to 29.8% by 2030 and 381.8% by 2050. Near term remains neutral, and forecasts are estimates with inherent uncertainty.
Yes. The forecast allows for reaching above $10 in the 2032-2033 window, with 2032 max $10.35 and 2033 max $10.34.
Current price is $4.26 and market cap is $634.51M.
Near term shows a NEUTRAL sentiment with RSI(14) at 70, SMA50 at $3.68, SMA200 at $5.29, support at $3.57, and resistance at $4.26. The 30-day range is $3.77 to $4.82.
MiMedx Group, Inc. Community Discussion
0Share your MiMedx Group, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.